Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Clinical failure associated with reduced susceptibility to caspofungin has been described in Candida albicans and C. parapsilosis. We report a case of Candida krusei infection that progressed despite caspofungin therapy. Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1.
Hakki
Morgan
M
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
Staab
Janet F
JF
Marr
Kieren A
KA
D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016469:Fungemia / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology* / Q000627:therapeutic use
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin